Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 2Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill ...

Key among these is the activation of signaling by RHO (another member of the RAS superfamily) and the up-regulation of kinases, some of which have the same substrates as ERK. Studies are needed to ...

"Some people may leave our platforms for virtue signaling, but I think the vast majority and many new users will find that these changes make the products better." Zuckerberg was replying to a ...

The authors declared no competing interests. Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01 ...